140 related articles for article (PubMed ID: 23155276)
1. Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolisation of hepatocellular carcinoma.
Iwazawa J; Hashimoto N; Ohue S; Mitani T
Anticancer Res; 2012 Nov; 32(11):5039-44. PubMed ID: 23155276
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
[TBL] [Abstract][Full Text] [Related]
3. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
[TBL] [Abstract][Full Text] [Related]
5. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
[TBL] [Abstract][Full Text] [Related]
6. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
Matsumoto T; Ichikawa H; Imai J; Hayashi T; Tomita K; Mine T; Kojima S; Watanabe N; Hasebe T
Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
[TBL] [Abstract][Full Text] [Related]
10. [External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer].
Liu MZ; Wang XS; Cai L; Gu MF; Liu H; Li Q; Cui NJ; Zhang YQ; Li GH; Li JQ
Ai Zheng; 2005 Jan; 24(1):82-6. PubMed ID: 15642207
[TBL] [Abstract][Full Text] [Related]
11. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors.
Lu W; Li Y; He X; Chen Y
Hepatogastroenterology; 2003; 50(54):2079-83. PubMed ID: 14696468
[TBL] [Abstract][Full Text] [Related]
12. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
Seki A; Hori S
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
[TBL] [Abstract][Full Text] [Related]
13. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
[TBL] [Abstract][Full Text] [Related]
14. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.
Miyayama S; Yamashiro M; Shibata Y; Hashimoto M; Yoshida M; Tsuji K; Toshima F; Matsui O
Jpn J Radiol; 2012 Apr; 30(3):263-70. PubMed ID: 22223074
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Kudo M; Imanaka K; Chida N; Nakachi K; Tak WY; Takayama T; Yoon JH; Hori T; Kumada H; Hayashi N; Kaneko S; Tsubouchi H; Suh DJ; Furuse J; Okusaka T; Tanaka K; Matsui O; Wada M; Yamaguchi I; Ohya T; Meinhardt G; Okita K
Eur J Cancer; 2011 Sep; 47(14):2117-27. PubMed ID: 21664811
[TBL] [Abstract][Full Text] [Related]
16. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of transcatheter arterial chemolipiodolization of miriplatin for multiple hepatocellular carcinoma].
Arai H; Kobayashi T; Izuka K; Ueno T; Mori K; Takizawa D; Toyoda M; Takayama H; Abe T
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2513-6. PubMed ID: 23235170
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M
Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
[TBL] [Abstract][Full Text] [Related]
19. Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study.
Goda Y; Morimoto M; Irie K; Kobayashi S; Ueno M; Moriya S; Tezuka S; Ohkawa S; Morinaga S; Numata K; Tanaka K; Maeda S
Jpn J Clin Oncol; 2017 Dec; 47(12):1151-1156. PubMed ID: 28977459
[TBL] [Abstract][Full Text] [Related]
20. Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization.
Lu W; Li YH; He XF; Zhao JB; Chen Y; Mei QL
Cardiovasc Intervent Radiol; 2008; 31(6):1133-40. PubMed ID: 18584240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
